dermveda ULTRA HEMORRHOID AND FISSURE

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
dermveda ULTRA HEMORRHOID AND FISSURE
Generic name
SULFUR, CURCUMA LONGA
Manufacturer
Celcius Corp.
Product type
HUMAN OTC DRUG
SPL set ID
044e0503-215b-4d57-96d9-62a54a8de4d1
SPL ID
304ebcc3-da32-48b6-bc8a-be557dd0c6ce
Version
1
Effective date
2026-08-10
Source export date
2026-10-27
Source partition
4
Source file
https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-27/a758d73d4d838a965005e6adf01b928e2da86f99be0f8bbaeeb95f3b7acbe418/drug-label-0004-of-0014.json.zip
Source manifest SHA-256
6be3667a3beefe6c0ead4c723ea963050533a2bc725a8044d58b07d18b258c55
Import run
20261027T193451Z
Imported at
2026-10-27 19:59:00
Harmonized routes table
Harmonized routes
TOPICAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings For external use only . Product is not FDA evaluated and will not cure Herpes, will not prevent future outbreaks and will not stop the spread of Herpes virus. When using this product • Apply the product exclusively to affected areas. • Avoid application near or around the eyes. • Do not share this product with others to mitigate the risk of infection or viral transmission. Stop use and ask a doctor if • If symptoms persist or inflammation increases after weeks of use or if the itch increases. • Increase in redness on skin. Pregnant or Breast Feeding • Ask a Health Professional before use. Keep out of reach of children . If swallowed, get medical help or contact a poison Control Center right away.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.